UTAH MEDICAL PRODUCTS INC
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
UTMD$72.86-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| UTAH MEDICAL PRODUCTS, INC. | ||||||
|---|---|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY | ||||||
| Years Ended December 31, 2025, 2024 and 2023 | ||||||
| (In thousands) | ||||||
| Accumulated | ||||||
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Retained · Stockholders' | ||||||
| Shares | Amount | Capital | Income | Earnings | Equity | |
| Balance at December 31, 2022 | 3,628 | $36 | $252 | $(12,039) | $126,006 | $114,255 |
| Shares issued upon exercise of employee stock options for cash | 2 | - | 117 | - | - | 117 |
| Stock option compensation expense | - | - | 225 | - | - | 225 |
| Common stock purchased and retired | - | - | - | - | - | - |
| Foreign currency translation adjustment | - | - | - | 1,381 | - | 1,381 |
| Common stock dividends | - | - | - | - | (4,300) | (4,300) |
| Net income | - | - | - | - | 16,635 | 16,635 |
| Balance at December 31, 2023 | 3,630 | $36 | $594 | $(10,658) | $138,341 | $128,313 |
| Shares issued upon exercise of employee stock options for cash | 8 | - | 390 | - | - | 390 |
| Stock option compensation expense | - | - | 256 | - | - | 256 |
| Common stock purchased and retired | (302) | (3) | (1,239) | - | (18,726) | (19,968) |
| Foreign currency translation adjustment | - | - | - | (1,249) | - | (1,249) |
| Common stock dividends | - | - | - | - | (4,189) | (4,189) |
| Net income | - | - | - | - | 13,874 | 13,874 |
| Balance at December 31, 2024 | 3,335 | $33 | $- | $(11,907) | $129,302 | $117,428 |
| Shares issued upon exercise of employee stock options for cash | - | - | - | - | - | - |
| Stock option compensation expense | - | - | 373 | - | - | 373 |
| Common stock purchased and retired | (149) | (1) | (373) | - | (7,981) | (8,355) |
| Foreign currency translation adjustment | - | - | - | 2,492 | - | 2,492 |
| Common stock dividends | - | - | - | - | (3,955) | (3,955) |
| Net income | - | - | - | - | 11,286 | 11,286 |
| Balance at December 31, 2025 | 3,186 | $32 | $- | $(9,416) | $128,652 | $119,268 |
| See accompanying notes to financial statements. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.